Enliven Therapeutics, Inc. (ELVN) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -19.29M | -15.84M | -13.28M | -17.06M | -24.13M | -17.2M | -12.19M | -20.43M | -23.36M | -12.48M | -15.89M | -12.05M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 20.04% | 7.93% | -8.91% | 16.53% | -3.28% | -37.82% | 23.29% | -69.6% | -12.08% | -53.25% | -146.53% | -69.13% |
| Net Income | -23.63M | -29.67M | -20.15M | -25.34M | -28.54M | -23.18M | -23.16M | -19.95M | -22.74M | -19.37M | -20.77M | -16.72M |
| Depreciation & Amortization | 280K | 101K | 62K | 154K | 74K | 80K | 80K | 78K | 79K | 77K | 78K | 74K |
| Stock-Based Compensation | 7.4M | 12.31M | 7.18M | 7.72M | 6.8M | 5.34M | 5.18M | 5.14M | 4.51M | 3.06M | 3.4M | 4.2M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.17M | 0 | 0 |
| Other Non-Cash Items | 93K | 198K | -221K | 87K | 40K | 1.07M | 719K | -1.32M | -582K | 2.46M | -1.76M | -831K |
| Working Capital Changes | -3.43M | 1.22M | -157K | 313K | -2.5M | -510K | 4.99M | -4.38M | -4.63M | 5.46M | 3.15M | 1.23M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -519K | 828K | -1.02M | 789K | 220K | 323K | -64K | -1.6M | 2.15M | -961K | -1.59M | -188K |
| Cash from Investing | 42.53M | 12.38M | -4.06M | -183.59M | 1.43M | 727K | 14.83M | -33.66M | -17.89M | 38.69M | -35.55M | -151.52M |
| Capital Expenditures | 0 | 0 | 1K | -139K | -20K | 0 | -22K | -2K | -20K | -14K | -16K | -88K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -40M | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 213K | 0 | 0 | 0 | 0 | 52.4M | 10M | 0 | 0 | 40M | 0 |
| Cash from Financing | 10.05M | 623K | -368K | 218.38M | 234K | 39.97M | 1.12M | 1.81M | 90.27M | 90K | -425K | -2.82M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 10.05M | 623K | -368K | 218.38M | 234K | -50.51M | 1.12M | 1.81M | 90M | 90K | -425K | -1.5M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 0 | 0 | 0 | 90.48M | 0 | 0 | 270K | 0 | 0 | -1.32M |
| Net Change in Cash | 33.29M | -2.84M | -17.7M | 17.73M | -22.47M | 23.5M | 3.75M | -52.29M | 49.02M | 26.35M | -51.87M | -166.39M |
| Free Cash Flow | -19.29M | -15.84M | -13.28M | -17.2M | -24.15M | -17.2M | -12.21M | -20.44M | -23.38M | -12.5M | -15.91M | -12.14M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 20.11% | 7.93% | -8.7% | 15.86% | -3.28% | -37.67% | 23.22% | -68.39% | -12% | -51.54% | -146.25% | -63.42% |
| FCF per Share | -0.31 | -0.28 | -0.21 | -0.33 | -0.48 | -0.35 | -0.25 | -0.43 | -0.56 | -0.30 | -0.39 | -0.30 |
| FCF Conversion (FCF/Net Income) | 0.82x | 0.53x | 0.66x | 0.67x | 0.85x | 0.74x | 0.53x | 1.02x | 1.03x | 0.64x | 0.77x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |